Holen Sie sich die Stockscreener-App
25.13
1.26%
-0.32
Handel nachbörslich:
25.13
Schlusskurs vom Vortag:
$25.45
Offen:
$25.5
24-Stunden-Volumen:
1.52M
Relative Volume:
0.73
Marktkapitalisierung:
$4.24B
Einnahmen:
$890.53M
Nettoeinkommen (Verlust:
$30.57M
KGV:
139.61
EPS:
0.18
Netto-Cashflow:
$80.53M
1W Leistung:
+5.59%
1M Leistung:
+19.78%
6M Leistung:
+27.11%
1J Leistung:
+59.76%
1-Tages-Spanne:
$25.12
$25.61
1-Wochen-Bereich:
$23.28
$25.88
52-Wochen-Spanne:
$13.40
$25.88
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Vergleichen Sie ACAD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
25.13 | 4.19B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
Acadia Pharmaceuticals at Canaccord Conference: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals stock hits 52-week high at 25.24 USD By Investing.com - Investing.com Australia
Acadia Pharmaceuticals stock hits 52-week high at 25.24 USD - Investing.com
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 11, 2025 - BioSpace
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
JMP Securities Boosts ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $38.00 - MarketBeat
HC Wainwright Has Bullish Forecast for ACAD FY2027 Earnings - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $17.00 at The Goldman Sachs Group - MarketBeat
Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion - TipRanks
UBS Raises Price Target for ACADIA Pharmaceuticals to $36 - AInvest
Results: ACADIA Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth - MSN
Acadia Pharmaceuticals shares rise 1.05% intraday after UBS raised price target to $36. - AInvest
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2025 Earnings Call Transcript - Insider Monkey
Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - 富途牛牛
ACADIA Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Shares Surge 3.07% to New Peak on Q2 Earnings, Patent Wins - AInvest
Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday - MSN
Acadia Pharmaceuticals Reports Strong Q2 2025 Growth - The Globe and Mail
ACADIA Pharmaceuticals Reports Strong Q2 2025 Earnings - TipRanks
Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates - MSN
Acadia Pharmaceuticals stock price target raised to $24 from $18 at Stifel - Investing.com Canada
Mizuho Maintains Neutral Rating, Raises Price Target for ACADIA Pharmaceuticals to $24 - AInvest
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $17 to $38 - 富途牛牛
Mizuho raises Acadia Pharmaceuticals stock price target on solid earnings By Investing.com - Investing.com Canada
Mizuho raises Acadia Pharmaceuticals stock price target on solid earnings - Investing.com
Acadia Pharmaceuticals price target raised to $38 from $37 at Citizens JMP - TipRanks
Acadia Pharmaceuticals price target raised to $27 from $23 at BofA - TipRanks
Acadia Pharmaceuticals Beats Q2 Earnings ForecastsNews and Statistics - IndexBox
Acadia Pharmaceuticals stock price target raised to $38 from $37 at Citizens JMP - Investing.com Australia
Acadia Pharmaceuticals shares rise 2.10% premarket after FDA approves expanded indication for AJOVY. - AInvest
Acadia Pharmaceuticals Raises Guidance As Sales Climb In Q2 - Finimize
Earnings call transcript: ACADIA Pharmaceuticals Q2 2025 beats forecasts By Investing.com - Investing.com Canada
Instagram Rolls Out New Features for Personalized Content Discovery and Sharing - AInvest
ACADIA Pharmaceuticals Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:ACAD) - Seeking Alpha
Earnings call transcript: ACADIA Pharmaceuticals Q2 2025 beats forecasts - Investing.com
Transcript : ACADIA Pharmaceuticals Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Acadia Pharmaceuticals Q2 Earnings Fall, Revenue Rises - MarketScreener
Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview - BioSpace
ACADIA Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Acadia: Q2 Earnings Snapshot - Connecticut Post
Neuren Pharma shares soar on Q2 royalties growth - Capital Brief
Revamping Acadia - BioCentury
Acadia Pharmaceuticals Q2 2025 slides: revenue up 9%, raises full-year guidance - Investing.com Australia
Acadia Pharmaceuticals to Present at Canaccord Genuity 45th Annual Growth Conference - AInvest
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - Lelezard
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):